Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $120,190.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider David M. Chao sold 7,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now directly owns 225,007 shares of the company's stock, valued at $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA traded down $0.54 during mid-day trading on Friday, reaching $15.75. 1,555,582 shares of the stock were exchanged, compared to its average volume of 526,428. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average price of $16.47 and a 200 day moving average price of $16.40. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The firm has a market capitalization of $2.08 billion, a PE ratio of -10.29 and a beta of 1.54.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth approximately $31,000. GAMMA Investing LLC lifted its position in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $171,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

CNTA has been the topic of several recent analyst reports. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Finally, Guggenheim reiterated a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.